- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere Embolization Spheres
Medtronic (NYSE: MDT) announced its U.S. launch of OptiSphere embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic. As quoted in the press release: Hypervascular tumors can present as malignant or benign and can be …
Medtronic (NYSE: MDT) announced its U.S. launch of OptiSphere embolization spheres, a resorbable embolic platform designed for embolization of hypervascular tumors. OptiSphere offers patients an alternative treatment option, a resorbable embolic, with comparable results to a permanent embolic.
As quoted in the press release:
Hypervascular tumors can present as malignant or benign and can be found in various anatomical structures. Physicians may choose to treat these tumors with various therapies including, but not limited to, embolization, microwave ablation, radiofrequency ablation, or cryoablation.
“Medtronic continues to seek opportunities to expand the therapies we offer to patients and the physicians who treat them. With increased and better quality of care, the cancer patient population is living longer with the disease and it is important that we continue to introduce therapies that help positively impact and improve their quality of life,”said Jeff Cambra, general manager of the Pain Therapies Interventional business, which is part of the Restorative Therapies Group at Medtronic. “We consider this launch to be a win for both sides of the healthcare pathway, as OptiSphere addresses patient concerns of having permanent implanted spheres left behind while enabling physicians to offer an innovative treatment option in their facilities.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â